CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic Analysis Review

Document Sample
CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic Analysis Review Powered By Docstoc
					         CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic
                                 Analysis Review

       Reference Code: GDME8444FSA                                                                                       Publication Date: AUG 2010

       1635 Village Center Circle, Suite Phone                                                        Revenue
                                                                +1 702 8397200                                           0.0 (million USD)
       250
       Las Vegas, NV                     Fax                                                          Net Profit         NA
       89134                                  Website           www.cvbt.com                          Employees          22
       United States                          Exchange          CVBT [Over The Counter]               Industry           Medical Equipment

      Company Overview
       Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs
       for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of
       new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth
       of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing
       Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States.

      Key Executives                                                                  SWOT Analysis
                     Name                                    Title                    CardioVascular BioTherapeutics, Inc., SWOT Analysis
       Daniel C. Montano                     Chairman                                 Strengths                Weaknesses

       John William Jacobs, PH.D.            Chief Operating Officer
                                                                                                                       Dependence on Single
                                                                                      Agreements
       Mickael A. Flaa                       Chief Financial Officer                                                   Supplier
       Grant Gordon                          Director                                 Proprietary Technology
                                                                                                                       Increased Presence of Debt
       Gary B. Abromovitz                    Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData                                                                     Opportunities                    Threats
      Share Data
                                                                                      Marketing Strategy               Emergence of
       CardioVascular BioTherapeutics, Inc.                                                                            Biogenerics/Biosimilars
       Share Price (USD) as on 26-Mar-2010                                  0.20      Molecules in Clinical
                                                                                      Development                      Tightening of FDA’s Regulatory
       EPS (USD)                                                            -0.27
                                                                                                  
				
DOCUMENT INFO
Description: Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States. This comprehensive SWOT profile of CardioVascular BioTherapeutics, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.